Major Drivers Propelling the Growth oh theAcute Respiratory Distress Syndrome (ARDS) Market Forward: Impact Of Increasing Pneumonia Prevalence On The Acute Respiratory Distress Syndrome (ARDS) Market
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Acute Respiratory Distress Syndrome (ARDS) Market In 2029?
The market size for acute respiratory distress syndrome (ARDS) has experienced robust growth in the recent past. It is projected to rise from $1.29 billion in 2024 to $1.41 billion in 2025, with a compound annual growth rate (CAGR) of 9.4%. Factors contributing to the historical growth include developments in critical care medicine, senior citizen population growth, advancements in rehabilitation for pulmonary conditions, and the use of multidisciplinary care teams.
The market size for acute respiratory distress syndrome (ards) is projected to experience substantial expansion in the upcoming years, reaching$2.15 billion by 2029 with a compound annual growth rate (CAGR) of 11.1%. The reasons behind this growth during the predicted period are related to global preparedness for healthcare, advancement in vaccine development, managing infectious diseases, incorporation of telemedicine, and patient-centric care models. The upcoming trends for this period includes the use of artificial lung devices, customized ventilation methods, lung protection ventilation techniques, and drug treatments tailored for different ARDS subtypes.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Acute Respiratory Distress Syndrome (ARDS) Market?
The surge in pneumonia cases is anticipated to stimulate the expansion of the acute respiratory distress syndrome (ARDS) market in the future. Pneumonia is a disease that can affect either one or both lungs, leading to the lung’s air pockets, known as alveoli, becoming filled with fluid or pus. The infection triggers an inflammatory response in the lungs, which heightens the permeability of blood vessels and causes fluid to leak into the alveoli. The accumulation of this fluid hampers the transfer of oxygen and carbon dioxide, resulting in respiratory distress. As an illustration, the Centre for Tropical Medicine and Global Health, a prominent UK-based healthcare research entity, reported a substantial increase in pneumonia cases in Kenya in November 2023, with the number skyrocketing to 793,864 in 2022-2023 from 477,186 in 2020-2021. Hence, the rising incidence of pneumonia is fueling the growth of the acute respiratory distress syndrome (ARDS) market.
Which Key Market Segments Comprise the Acute Respiratory Distress Syndrome (ARDS) Market and Drive Its Revenue Growth?
The acute respiratory distress syndrome (ards)market covered in this report is segmented –
1) By Type: Diagnosis; Treatment
2) By Cause: COVID-19 Disease 2019 (COVID-19); Sepsis; Inhalation Of Harmful Substances; Severe Pneumonia; Other Causes
3) By Severity: Mild; Moderate; Severe
4) By End User: Hospitals; Clinics; Ambulatory Service Centers; Other End Users
Subsegments:
1) By Diagnosis: Imaging Tests; Blood Tests; Lung Function Tests; Other Diagnostic Methods
2) By Treatment: Mechanical Ventilation; Medications; Extracorporeal Membrane Oxygenation (ECMO); Supportive Care; Other Treatment Options
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13005&type=smp
Which Areas Are Leading Regions in the Acute Respiratory Distress Syndrome (ARDS) Market Expansion Across the Globe?
North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2024. The regions covered in acute respiratory distress syndrome (ARDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Are the Key Market Trends in theAcute Respiratory Distress Syndrome (ARDS) Market Over the Coming Years?
Big players in the acute respiratory distress syndrome (ARDS) market are aiming to maintain their market standing by creating novel drugs and supplements like Aviptadil, HSP90 inhibitors, and others. Aviptadil is a manufactured vasoactive intestinal peptide (VIP) that attaches distinctively to lung alveolar type II cell receptors. For example, in November 2022, Zuventus Healthcare Ltd., a pharmaceutical manufacturing firm in India, introduced Aviptadil for the treatment of acute respiratory distress syndrome. The supplement, a vasoactive intestinal peptide, boosts breathing and decreases fatality rates in ARDS patients through its capability to shield and regrow Type-2 Pneumocytes, replenish Type-1 Pneumocytes, amplify surfactant synthesis, and inhibit interleukin 6 (IL-6) and tumor necrosis factor (TNF)-alpha.
View the full report here:
How Is the Acute Respiratory Distress Syndrome (ARDS) Market Conceptually Defined?
Acute respiratory distress syndrome (ARDS) is a potentially fatal illness characterized by non-compliant, or stiff lungs and low oxygenation. It is an acute, diffuse and inflammatory form of lung injury that can occur in seriously ill patients. Acute respiratory distress syndrome (ARDS) treatment involves mechanical ventilation with low tidal volumes and positive end-expiratory pressure (PEEP) to support oxygenation and prevent lung injury.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13005
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
